

Monitoring Drug Therapy
On Demand

Sponsored by



Agenda

Session Duration	Topic	Presenter(s)
30 minutes	<p>Immunosuppressive Therapy</p> <ul style="list-style-type: none"> Understand the difference between pharmacokinetic and pharmacodynamic monitoring. Understand the need for the pharmacokinetic monitoring of cyclosporine (and in certain circumstances, mycophenolate mofetil and leflunomide) when administering systemic immunosuppressive therapy. Understand the value of pharmacodynamic monitoring for all immunosuppressive agents. 	<i>Dr. Andrew Mackin</i>
30 minutes	<p>Anticonvulsant Therapy</p> <ul style="list-style-type: none"> Review recommended therapeutic drug monitoring protocols for the most commonly used anticonvulsant medications in canine and feline patients. Identify appropriate blood work recommendations for patients receiving anticonvulsant therapy. Interpret anticonvulsant drug monitoring results and apply this information to clinical decision-making for individual patients. 	<i>Dr. Missy Carpentier</i>
30 minutes	<p>Drug Therapy for Patients with Liver Disease</p> <ul style="list-style-type: none"> Understand how drugs are cleared by the liver. Understand the most common tests to identify liver injury and whether these are predictive of hepatic drug clearance. Understand the best choices for treatment of specific conditions in animals with liver injury. 	<i>Dr. Mark Papich</i>
60 minutes	<p>Drug Therapy for Patients with Renal Disease</p> <ul style="list-style-type: none"> Understand how drugs are cleared by the kidney. Discuss when and how to amend dose in patients with renal dysfunction. Review recommended drug monitoring protocols for commonly used medications for kidney disease. 	<i>Dr. JD Foster</i> <i>Dr. Jessica Quimby</i>
60 minutes	<p>Panel Discussion</p> <ul style="list-style-type: none"> Discuss immunosuppressive therapy. Explore topics related to anticonvulsant therapy. Explore questions specific to drug therapy for patients with liver disease. 	<i>Dr. Missy Carpentier</i> <i>Dr. Mark Papich</i> <i>Dr. JD Foster</i> <i>Dr. Jessica Quimby</i> <i>Moderator: Dr. Andrew Mackin</i>

**Monitoring Drug Therapy
On Demand**

Sponsored by



Agenda (cont.)		
Session Duration	Topic	Presenter(s)
30 minutes	<p>Monitoring Trilostane Therapy</p> <ul style="list-style-type: none"> • Understand the available data on cortisol monitoring. • List the strengths and weaknesses of trilostane monitoring approaches. • Determine when the monitoring approach needs to be adjusted for a specific patient. 	<i>Dr. Patty Lathan</i>
30 minutes	<p>Monitoring Mineralocorticoid Therapy in Addisons</p> <ul style="list-style-type: none"> • Gain familiarity with the original field trials that led to current DOCP dosing guidelines. • Understand the benefits and limitations of electrolyte monitoring for assessing mineralocorticoid status. • Use current evidence to design safe, cost-effective, and physiologically appropriate dosing protocols for DOCP. 	<i>Dr. Daniel Langlois</i>
60 minutes	<p>Antimicrobial Therapy/Avoiding Antimicrobial Resistance</p> <ul style="list-style-type: none"> • Describe recent breakpoint revisions and the clinical implications of the susceptible dose dependent category. • Interpret susceptibility reports in the context of pharmacokinetics, pharmacodynamics, and infection site. • Apply pharmacologic principles to select the most appropriate available therapy for extensively resistant infections when optimal options are limited. 	<i>Dr. Cooper Brookshire</i>
60 minutes	<p>Pharmacogenomics</p> <ul style="list-style-type: none"> • Describe when it is appropriate to determine a dog's MDR1 genotype prior to drug therapy. • Describe when it is appropriate to determine a cat's MDR1 genotype prior to drug therapy. • Describe when it is appropriate to determine a dog's DEPOHGEN genotype prior to surgery. 	<i>Dr. Katrina Mealey</i>

**Monitoring Drug Therapy
On Demand**

Sponsored by



Agenda (cont.)		
Session Duration	Topic	Presenter(s)
60 minutes	<p>Panel Discussion</p> <ul style="list-style-type: none"> • Explore topics related to monitoring mineralocorticoid therapy in Addison's. • Discuss antimicrobial therapy and topics related to avoiding antimicrobial resistance. • Explore issues with pharmacogenomics. 	<p><i>Dr. Patty Lathan Dr. Daniel Langlois Dr. Cooper Brookshire Dr. Katrina Mealey</i></p> <p><i>Moderator: Dr. Andrew Mackin</i></p>